Dementia with Lewy bodies — from scientific knowledge to clinical insights

@article{Arnaoutoglou2018DementiaWL,
  title={Dementia with Lewy bodies — from scientific knowledge to clinical insights},
  author={N. Arnaoutoglou and J. O'Brien and B. Underwood},
  journal={Nature Reviews Neurology},
  year={2018},
  volume={15},
  pages={103-112}
}
Dementia with Lewy bodies (DLB) is the underlying aetiology of 10–15% of all cases of dementia and as such is a clinically important diagnosis. In the past few years, substantial advances have been made in understanding the genetics and pathology of this condition. For example, research has expanded our knowledge of the proteinaceous inclusions that characterize the disease, has provided an appreciation of the role of disease-associated processes such as inflammation and has revealed an… Expand

Figures, Tables, and Topics from this paper

Epigenetic regulation in the pathophysiology of Lewy body dementia
TLDR
The role of epigenetic mechanisms as potential key mediators of gene-environment interactions in the development of dementia is focused on, suggesting a central involvement of epigenetics in DLB but conclusive evidence is scarce. Expand
Evidence that the Kennedy and polyamine pathways are dysregulated in human brain in cases of dementia with Lewy bodies
TLDR
Altered brain levels of putrescine and O-phosphocholine indicate that the Kennedy pathway and polyamine metabolism are perturbed in DLB, accompanied by a consistent underlying trend of lipid dysregulation. Expand
Differentiating dementia with Lewy bodies from Alzheimer's disease and Parkinson's disease dementia: an update on imaging modalities
TLDR
An overview of both established and evolving imaging methods that can improve diagnostic accuracy and improve management of dementia with Lewy bodies. Expand
Depressive Symptoms and Cognitive Improvement in Patients with Dementia with Lewy Bodies.
TLDR
Depressive symptoms at baseline were related to a higher probability of a cognitive improvement at one-year follow-up and immediate and delayed verbal memory function showed significant improvement during one year in improved patients compared to non-improved patients. Expand
Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update—I. Hypokinetic-rigid movement disorders
  • K. Jellinger
  • Psychology, Medicine
  • Journal of Neural Transmission
  • 2019
TLDR
A timely overview of the neuropathology and pathogenesis of the major extrapyramidal movement disorders in two parts, the first one dedicated to hypokinetic-rigid forms and the second to hyperkinetic disorders. Expand
Altered structural connectivity networks in dementia with lewy bodies.
TLDR
The results suggest a marked impairment in large-scale brain structural networks in DLB, mirroring functional connectivity networks disruption. Expand
Animal models of synucleinopathies and how they could impact future drug discovery and delivery efforts
  • K. Jellinger
  • Biology, Medicine
  • Expert opinion on drug discovery
  • 2019
TLDR
Further attention should be focused on the development of new models to enable better insight into the pathology of these proteinopathies as the basis for the future development of real disease-modifying or even preventive modalities. Expand
Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease
TLDR
Plasma phospho‐tau might be a useful marker for Alzheimer's co‐pathology in Lewy body disease with dementia and predicted abnormal tau‐PET status and β‐amyloid status. Expand
Viewpoint on the role of tissue maintenance in ageing: focus on biomarkers of bone, cartilage, muscle, and brain tissue maintenance
TLDR
The hypothesis that disturbances in the process of tissue maintenance are an important common denominator that may lie in between specific hallmarks of ageing and age-related functional decline is put forward. Expand
Apolipoprotein E regulates lipid metabolism and α-synuclein pathology in human iPSC-derived cerebral organoids
  • Jing Zhao, Wenyan Lu, +20 authors G. Bu
  • Medicine
  • Acta Neuropathologica
  • 2021
APOE4 is a strong genetic risk factor for Alzheimer’s disease and Dementia with Lewy bodies; however, how its expression impacts pathogenic pathways in a human-relevant system is not clear. HereExpand
...
1
2
...

References

SHOWING 1-10 OF 196 REFERENCES
DEMENTIA WITH LEWY BODIES
TLDR
The current state of scientific knowledge on DLB is reviewed to show that treatment with cholinesterase inhibitors is well tolerated by most patients and substantially improves cognitive and neuropsychiatric symptoms. Expand
The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis
TLDR
Prodromal diagnosis is of great importance in research, where identifying Lewy body disease at an earlier stage may allow researchers to investigate the initial phases of dementia pathophysiology, develop treatments designed to interrupt the development of the dementia syndrome and accurately identify the patients most likely to benefit from these treatments. Expand
Neuroimaging characteristics of dementia with Lewy bodies
TLDR
It is argued that the multimodal identification of DLB-specific biomarkers has the potential to improve ante-mortem diagnosis and contribute to the authors' understanding of the pathological background ofDLB and its progression. Expand
[Dementia with Lewy bodies].
  • E. Mori
  • Medicine
  • Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics
  • 2000
TLDR
Recent clinical and research findings are reviewed to facilitate clinical recognition of DLB, characterized by the presence of progressive dementia without severe memory disorders at the early stage, with significant cognitive fluctuations, well-formed recurrent visual hallucinations, and spontaneous Parkinsonism. Expand
Clinical imaging in dementia with Lewy bodies
TLDR
There are suggestions that MIBG may be better in the differentiation of vascular parkinsonism from DLB than DAT scans but may have lower sensitivity for detecting DLB compared with the 80% sensitivity seen in DAT imaging. Expand
Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies.
TLDR
The aim of this review was to estimate the accuracy of DAT imaging for the diagnosis of DLB in people with dementia in secondary care (specialist dementia services), and to calculate sensitivities, specificities, and their 95% confidence intervals. Expand
Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study
TLDR
Despite the small sample size for a genome-wide association study, and acknowledging the potential biases from ascertaining samples from multiple locations, this study presents the most comprehensive and well powered genetic study in dementia with Lewy bodies so far. Expand
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study.
TLDR
This study confirms features suggested to predict these disorders, except for the early presence of postural imbalance, which is not indicative of either disorder. Expand
Prodromal dementia with Lewy bodies
TLDR
The long prodromal phase of DLB provides a critical opportunity for potential intervention with disease‐modifying therapy, but only if the diversity in the clinical courses ofDLB is able to clearly identify the diversity. Expand
Exome sequencing in dementia with Lewy bodies
TLDR
Although known pathogenic mutations in neurodegenerative disease genes are uncommon in DLB, known genetic risk factors are present in >60% of cases and APOE ɛ4 not only modifies disease risk, but also modulates the rate of disease progression. Expand
...
1
2
3
4
5
...